Structures by: Olejniczak A.
Total: 123
DabcoHClO4
C6H13N2,ClO4
Crystal Growth & Design (2013) 13, 7 2872
a=8.7660(9)Å b=9.7580(12)Å c=10.6754(11)Å
α=90.00° β=90.00° γ=90.00°
DabcoHClO4
C6H13N2,ClO4
Crystal Growth & Design (2013) 13, 7 2872
a=8.8708(10)Å b=9.7540(10)Å c=5.3493(10)Å
α=90.00° β=90.00° γ=90.00°
DabcoHClO4
C6H13N2,ClO4
Crystal Growth & Design (2013) 13, 7 2872
a=8.7689(9)Å b=9.7602(10)Å c=10.6740(10)Å
α=90.00° β=90.00° γ=90.00°
DabcoHClO4
C6H13N2,ClO4
Crystal Growth & Design (2013) 13, 7 2872
a=8.8777(9)Å b=9.7614(12)Å c=10.6840(12)Å
α=90.00° β=90.00° γ=90.00°
DabcoHClO4
C6H13N2,ClO4
Crystal Growth & Design (2013) 13, 7 2872
a=8.8779(8)Å b=9.7606(11)Å c=5.3422(5)Å
α=90.00° β=90.00° γ=90.00°
DabcoHClO4
C6H13N2,ClO4
Crystal Growth & Design (2013) 13, 7 2872
a=8.7830(9)Å b=9.7595(12)Å c=5.3416(6)Å
α=90.00° β=90.00° γ=90.00°
DabcoHI hydarte
C6H13N2,H2O,I
Crystal Growth & Design (2011) 11, 6 2250
a=10.7310(11)Å b=8.2648(14)Å c=9.6593(17)Å
α=90.00° β=90.00° γ=90.00°
DabcoHI hydarte
C6H15IN2O
Crystal Growth & Design (2011) 11, 6 2250
a=14.896(3)Å b=21.236(3)Å c=30.962(5)Å
α=90.00° β=90.00° γ=90.00°
1,4-diazabicyclo[2.2.2]octane dihydrobromide, dabco dihydrobromide, dabco2HBr
C6H14N2,2Br
Crystal Growth & Design (2011) 11, 11 4892
a=7.0917(13)Å b=12.280(3)Å c=11.4693(18)Å
α=90.00° β=90.00° γ=90.00°
1,4-diazabicyclo[2.2.2]octane dihydrobromide semihydrate, dabco2HBr*0.5H2O
2(C6H14N2),H2O,4(Br)
Crystal Growth & Design (2011) 11, 11 4892
a=14.3848(18)Å b=12.4619(12)Å c=11.3029(11)Å
α=90.00° β=90.00° γ=90.00°
Dabco dihydrobromide monohydrate, dabco2HBr*H2O
C6H14N2,H2O,2(Br)
Crystal Growth & Design (2011) 11, 11 4892
a=15.015(3)Å b=12.486(2)Å c=11.2364(16)Å
α=90.00° β=90.00° γ=90.00°
Dabco dihydrobromide monohydrate, dabco2HBr*H2O
C6H14N2,H2O,2(Br)
Crystal Growth & Design (2011) 11, 11 4892
a=7.2844(19)Å b=10.918(4)Å c=5.663(4)Å
α=90.00° β=90.00° γ=90.00°
Dabco dihydrobromide monohydrate, dabco2HBr*H2O
C6H14N2,H2O,2(Br)
Crystal Growth & Design (2011) 11, 11 4892
a=7.185(3)Å b=12.382(6)Å c=11.119(3)Å
α=90.00° β=90.00° γ=90.00°
Dabco dihydrobromide monohydrate, dabco2HBr*H2O
C6H14N2,H2O,2(Br)
Crystal Growth & Design (2011) 11, 11 4892
a=6.516(4)Å b=12.037(3)Å c=6.792(3)Å
α=90.00° β=113.06(5)° γ=90.00°
Thiourea monohydrate
CH4N2S,H2O
Crystal Growth & Design (2013) 13, 1 121
a=5.995(2)Å b=8.996(10)Å c=7.986(4)Å
α=90.00° β=98.63(4)° γ=90.00°
Thiourea monohydrate
CH4N2S,H2O
Crystal Growth & Design (2013) 13, 1 121
a=5.9685(8)Å b=8.820(4)Å c=7.9218(13)Å
α=90.00° β=98.930(13)° γ=90.00°
Thiourea hydrate
3(CH4N2S),2(H2O)
Crystal Growth & Design (2013) 13, 1 121
a=8.020(2)Å b=8.649(6)Å c=16.645(11)Å
α=90.00° β=90.78(5)° γ=90.00°
Thiourea hydrate
3(CH4N2S),2(H2O)
Crystal Growth & Design (2013) 13, 1 121
a=7.968(2)Å b=8.5877(13)Å c=16.554(9)Å
α=90.00° β=91.01(4)° γ=90.00°
6-azido-1,2,4-triazolo[4,3-b]pyridazine
C5H3N7
Acta Crystallographica Section B (2020) 76, 6
a=7.8356(16)Å b=18.074(3)Å c=8.88(3)Å
α=90° β=94.24(7)° γ=90°
3-methyl-6-azido-1,2,4-triazolo[4,3-b]pyridazine
C6H5N7,0.4(O)
Acta Crystallographica Section B (2020) 76, 6
a=28.1659(3)Å b=28.1659(3)Å c=4.12335(8)Å
α=90° β=90° γ=90°
3-methyl-6-azido-1,2,4-triazolo[4,3-b]pyridazine
C6H5N7,0.4(O)
Acta Crystallographica Section B (2020) 76, 6
a=28.1314(4)Å b=28.1314(4)Å c=4.09378(10)Å
α=90° β=90° γ=90°
3-methyl-6-azido-1,2,4-triazolo[4,3-b]pyridazine
C6H5N7,0.4(O)
Acta Crystallographica Section B (2020) 76, 6
a=28.1081(4)Å b=28.1081(4)Å c=4.06918(11)Å
α=90° β=90° γ=90°
Quinuclidinum 2,6-dichloro-4-nitrophenolate
C13H16Cl2N2O3
To be published
a=11.9779(6)Å b=11.4024(5)Å c=11.2258(7)Å
α=90° β=105.862(5)° γ=90°